Oncolytics Biotech Inc

Oncolytics Biotech Inc., a development-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. Its lead product is pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of solid tumors and hematological malignancies. Show More...

  • Website https://www.oncolyticsbiotech.com
  • Sector Healthcare
  • Industry Biotechnology
  • Last Quote 0.34 USD
  • Last Updated 30-05-2025
  • External Links Yahoo Finance Morningstar Ratios
  •   2010-12 2011-12 2012-12 2013-12 2014-12 2015-12 2016-12 2017-12 2018-12 2019-12 TTM
    Earnings Per Share CAD -3.71 -3.9 -4.56 -2.66 -2.0 -1.14 -1.2 -1.12 -1.06 -1.5 -1.27
    Dividends CAD
    Payout Ratio % *
    Shares Mil 7.0 7.0 8.0 9.0 9.0 12.0 13.0 14.0 16.0 22.0 27.0
    Book Value Per Share * USD 5.86 5.17 1.84 2.91 1.29 1.61 0.91 0.64 0.38 0.08 0.43
    Free Cash Flow Per Share * USD -2.76 -2.59 -4.31 -2.96 -1.98 -0.91 -0.77 -0.93 -0.52 -0.67
    Return on Assets % -49.92 -72.2 -125.2 -93.57 -82.0 -61.57 -71.85 -94.91 -103.21 -191.89 -108.93
    Financial Leverage (Average) 1.06 1.22 1.49 1.27 1.24 1.11 1.38 2.19 2.4 1.47
    Return on Equity % -54.5 -81.3 -164.19 -127.2 -103.35 -71.3 -85.62 -164.62 -235.33 -190.75
    Return on Invested Capital % -54.65 -82.17 -165.36 -128.71 -104.22 -72.06 -86.31 -165.63 -237.1 -938.09 -184.39
    Interest Coverage
    Current Ratio 17.38 5.48 2.97 4.61 4.94 9.94 3.55 3.41 5.13 1.47 7.89
    Quick Ratio 17.27 5.37 2.93 4.55 4.85 9.75 3.48 3.18 4.89 1.26 7.14
    Debt/Equity